Clinical Trials - In Follow-up

The clinical trials listed in this section are no longer recruiting new patients and some patients may still be receiving treatment. These trials are still monitoring their patients, collecting information and analysing the results with the aim of achieving the study’s objectives. Members can review the Trial Report in the Members Area.

Filter AGITG trials by

A Randomised, double-blinded phase II study of gemcitabine and nab‐paclitaxel with CEND‐1 or placebo in patients with untreated metastatic pancreatic ductal adenocarcinoma Read More

Three or five years of adjuvant imatinib for the treatment of patients with operable GIST with a high risk of relapse: A randomized phase III study. Read More

Neoadjuvant Immune-Chemo-Radiotherapy in operable oesophageal and gastro-oesophageal junction cancers with Carboplatin Paclitaxel Radiotherapy and Avelumab – a Trial assessing feasibility and preliminary Efficacy Read More

This study aims to demonstrate that a chemotherapy decision incorporating ctDNA results in addition to standard pathologic risk assessment will reduce the number of patients receiving adjuvant chemotherapy. Read More

This study aims to demonstrate that a ctDNA informed approach to chemotherapy, following surgery for localised pancreatic cancer, could lead to a reduction in the proportion of patients with detectable ctDNA after completion of treatment compared to standard of care. Read More

The purpose of the DYNAMIC-III study is to determine that a chemotherapy decision based on the presence or absence of circulating tumour DNA after surgery for stage III colorectal cancer, will be more effective than standard of care treatment as measured by how many patients remain cancer free at 3 years. Read More

The aim of ACTICCA-1 is to determine whether treating patients with chemotherapy following surgery for cancer of the biliary tract helps to reduce cancer recurrence. Read More

The purpose of TOPGEAR is to investigate the benefit of adding radiation (chemoradiotherapy) to chemotherapy and surgery to treat and improve the overall survival in patients undergoing surgery for resectable stomach cancer. Read More

This randomised phase II trial aims to evaluate the effect of simvastatin (SIM) on efficacy and toxicity of pCRT in rectal cancer patients, and on systemic and local inflammatory responses. Read More